Informações de AbbVie Inc | Histórico, dados financeiros e desempenho de mercado

Informações de AbbVie Inc Empresa

AbbVie Inc. is a global, diversified research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.

Informações da empresa

Código da empresaABBV

Nome da EmpresaAbbVie Inc

Data de listagemJan 02, 2013

Fundado em2012

CEOMr. Robert A. Michael, CPA

Funcionários55000

Tipo de TítulosOrdinary Share

Fim do ano fiscalJan 02

Endereço1 N Waukegan Rd

CidadeNORTH CHICAGO

Bolsa de ValoresNYSE Consolidated

PaísUnited States of America

Código postal60064

Telefone18479327900

Sitehttps://www.abbvie.com/

Código da empresaABBV

Data de listagemJan 02, 2013

Fundado em2012

Executivos da Empresa

Nome

Nome/Posição

Posição

Ações Detidas

Variação

Mr. Richard A. Gonzalez

Executive Chairman of the Board

386.48K

-2.18%

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

183.77K

-17.22%

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

133.43K

--

Mr. Glenn Fletcher Tilton

Independent Director

50.71K

--

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.28K

+16.15%

Mr. Edward J. (Ed) Rapp

Independent Director

41.74K

--

Ms. Roxanne S. Austin, CPA

Lead Independent Director

37.26K

--

Dr. Robert J. Alpern, M.D.

Independent Director

34.44K

--

Mr. Frederick H. (Rick) Waddell

Independent Director

27.75K

--

Ms. Melody B. Meyer

Independent Director

15.29K

--

Ver Mais

Nome

Nome/Posição

Posição

Ações Detidas

Variação

Mr. Richard A. Gonzalez

Executive Chairman of the Board

386.48K

-2.18%

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

183.77K

-17.22%

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

133.43K

--

Mr. Glenn Fletcher Tilton

Independent Director

50.71K

--

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.28K

+16.15%

Mr. Edward J. (Ed) Rapp

Independent Director

41.74K

--

Detalhamento da Receita

Moeda: USDTempo de atualização: qua, 2 de abr

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

Immunology-SKYRIZI

11.72B

20.80%

Immunology-HUMIRA

8.99B

15.96%

Immunology-RINVOQ

5.97B

10.60%

Hematologic Oncology-IMBRUVICA

3.35B

5.94%

Neuroscience-Botox Therapeutic

3.28B

5.83%

Other

23.02B

40.87%

Por RegiãoUSD

Nome

Receita

Proporção

United States

40.78B

72.39%

International

11.51B

20.42%

All other countries

3.03B

5.38%

Germany

1.47B

2.60%

Japan

1.12B

1.99%

Other

-1.57B

-2.79%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Immunology-SKYRIZI

11.72B

20.80%

Immunology-HUMIRA

8.99B

15.96%

Immunology-RINVOQ

5.97B

10.60%

Hematologic Oncology-IMBRUVICA

3.35B

5.94%

Neuroscience-Botox Therapeutic

3.28B

5.83%

Other

23.02B

40.87%

Acionista

Tempo de atualização: sex, 21 de fev

Estatísticas do Acionista

Tipo

Estatísticas do Acionista

Acionista

Proporção

The Vanguard Group, Inc.

9.74%

BlackRock Institutional Trust Company, N.A.

5.09%

State Street Global Advisors (US)

4.50%

Geode Capital Management, L.L.C.

2.10%

Capital Research Global Investors

1.92%

Other

76.65%

Estatísticas do Acionista

Acionista

Proporção

The Vanguard Group, Inc.

9.74%

BlackRock Institutional Trust Company, N.A.

5.09%

State Street Global Advisors (US)

4.50%

Geode Capital Management, L.L.C.

2.10%

Capital Research Global Investors

1.92%

Other

76.65%

Tipo

Acionista

Proporção

Investment Advisor

33.85%

Investment Advisor/Hedge Fund

29.79%

Research Firm

2.90%

Bank and Trust

2.23%

Pension Fund

2.22%

Sovereign Wealth Fund

1.52%

Insurance Company

0.63%

Hedge Fund

0.51%

Foundation

0.12%

Other

26.23%

Instituição Participações

Tempo de atualização: qui, 20 de fev

Período do Relatório

Nº de instituições

Ações detidas

Proporção

Variação

2025Q1

5158

1.32B

74.38%

+12.54M

2024Q4

5219

1.31B

74.47%

+8.91M

2024Q3

4974

1.30B

73.54%

-7.44M

2024Q2

4916

1.30B

73.53%

+2.27M

2024Q1

4930

1.29B

72.58%

-1.47M

2023Q4

4882

1.28B

72.31%

-1.48M

2023Q3

4694

1.27B

71.87%

-12.06M

2023Q2

4688

1.26B

71.51%

-30.42M

2023Q1

4658

1.27B

71.97%

-18.58M

2022Q4

4628

1.27B

71.69%

-10.55M

Ver Mais

Atividade dos Acionistas

Nome

Ações detidas

Proporção

Variação

Chg %

Data

The Vanguard Group, Inc.

172.31M

9.74%

+1.45M

+0.85%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

90.08M

5.09%

+893.98K

+1.00%

Dec 31, 2024

State Street Global Advisors (US)

79.62M

4.5%

+553.55K

+0.70%

Dec 31, 2024

Geode Capital Management, L.L.C.

37.14M

2.1%

+983.89K

+2.72%

Dec 31, 2024

Capital Research Global Investors

33.98M

1.92%

+778.13K

+2.34%

Dec 31, 2024

JP Morgan Asset Management

33.90M

1.92%

+881.83K

+2.67%

Dec 31, 2024

Capital International Investors

28.53M

1.61%

-8.25M

-22.44%

Dec 31, 2024

Charles Schwab Investment Management, Inc.

27.44M

1.55%

+3.60M

+15.10%

Dec 31, 2024

Norges Bank Investment Management (NBIM)

25.10M

1.42%

+2.62M

+11.64%

Dec 31, 2024

Morgan Stanley Smith Barney LLC

22.68M

1.28%

+844.34K

+3.87%

Dec 31, 2024

Ver Mais

ETFs Relacionados

Tempo de atualização: qua, 2 de abr

Nome

Proporção

First Trust Morningstar Dividend Leaders Index Fund

9.82%

First Trust NASDAQ Pharmaceuticals ETF

8.98%

VanEck Pharmaceutical ETF

7.38%

Proshares Ultra Health Care

6.8%

Health Care Select Sector SPDR Fund

6.8%

iShares U.S. Healthcare ETF

6.61%

Goldman Sachs Future Health Care Equity ETF

6.07%

Fidelity MSCI Health Care Index ETF

5.92%

Invesco Pharmaceuticals ETF

5.84%

Themes US Cash Flow Champions ETF

5.7%

Ver Mais

First Trust Morningstar Dividend Leaders Index Fund

Proporção9.82%

First Trust NASDAQ Pharmaceuticals ETF

Proporção8.98%

VanEck Pharmaceutical ETF

Proporção7.38%

Proshares Ultra Health Care

Proporção6.8%

Health Care Select Sector SPDR Fund

Proporção6.8%

iShares U.S. Healthcare ETF

Proporção6.61%

Goldman Sachs Future Health Care Equity ETF

Proporção6.07%

Fidelity MSCI Health Care Index ETF

Proporção5.92%

Invesco Pharmaceuticals ETF

Proporção5.84%

Themes US Cash Flow Champions ETF

Proporção5.7%

Dividendo

Um total de 48.58B USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro das ações

Data de pagamento

Data de ex-dividendo

Oct 30, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025

Jan 15, 2025

Feb 14, 2025

Jan 15, 2025

Sep 06, 2024

ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option

Oct 15, 2024

Nov 15, 2024

Oct 15, 2024

Jun 21, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option

Jul 15, 2024

Aug 15, 2024

Jul 15, 2024

Feb 15, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option

Apr 15, 2024

May 15, 2024

Apr 12, 2024

Oct 27, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Feb 15, 2024 going ex on Jan 12, 2024 with reinvestment option

Jan 16, 2024

Feb 15, 2024

Jan 12, 2024

Sep 11, 2023

ABBV.NB Final Cash Dividend of gross USD 1.48 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option

Oct 13, 2023

Nov 15, 2023

Oct 12, 2023

Jun 22, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option

Jul 14, 2023

Aug 15, 2023

Jul 13, 2023

Feb 16, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on May 15, 2023 going ex on Apr 13, 2023 with reinvestment option

Apr 14, 2023

May 15, 2023

Apr 13, 2023

Oct 28, 2022

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Feb 15, 2023 going ex on Jan 12, 2023 with reinvestment option

Jan 13, 2023

Feb 15, 2023

Jan 12, 2023

Sep 09, 2022

ABBV.NB Final Cash Dividend of gross USD 1.41 paid on Nov 15, 2022 going ex on Oct 13, 2022 with reinvestment option

Oct 14, 2022

Nov 15, 2022

Oct 13, 2022

Ver Mais

Desdobramento de Ações

Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados

AbbVie Inc

186.960USD

AbbVie Inc

186.960

Visão Geral

Empresa